Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,003.28 +2.50 (+0.25%) Streaming Delayed Price Updated: 10:39 AM EDT, Jun 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation August 01, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS July 29, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 Biotech Stocks to Buy for Long-Term Gains July 13, 2023 The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. Via MarketBeat Topics ETFs Economy Exposures Interest Rates Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading May 19, 2023 Via Investor Brand Network Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading March 23, 2023 Via Investor Brand Network $1 Billion Deal For Moderna To Expand Product Pipeline in China July 06, 2023 Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher Via MarketBeat Topics ETFs Economy Exposures COVID-19 Economy Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023 June 29, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm June 29, 2023 From The Schall Law Firm Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm June 28, 2023 From The Schall Law Firm Via Business Wire Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema June 27, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler June 27, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma May 25, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations May 25, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine May 21, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 May 19, 2023 $75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations May 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation May 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales May 05, 2023 Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. Via MarketBeat Regeneron Reports First Quarter 2023 Financial and Operating Results May 04, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research May 02, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy April 26, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy April 26, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary April 17, 2023 Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent Director From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases April 17, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations April 11, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023 April 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) March 29, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases March 28, 2023 From Sonoma Biotherapeutics, Inc. Via Business Wire Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases March 28, 2023 Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Sanofi, Regeneron Shares Pop On Big News About COPD Treatment March 27, 2023 Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. Via MarketBeat < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.